Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative versus postoperative Conbercept around panretinal photocoagulation in high-risk proliferative diabetic retinopathy without macular edema
ChiCTR1900024203Phase 4Recruiting
- Sponsor
- Shandong Eye Institute
- Start
- Jul 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of conbercept in diabetic retinopathy (DR) (2 arms), sponsored by Shandong Eye Institute. Primary endpoints: Macular blood flow density, Visual field and 1 more. Started Jul 2019; status: recruiting.
02
Drugs
conbercept
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on ChiCTR1900024203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024203.